Revenue - ASKA Pharmaceutical Co. Ltd. (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
---|---|---|---|
Feb. 27, 2017 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
Deferred Revenue Arrangement [Line Items] | |||
Milestone payments | $ 12,573 | $ 1,655 | |
ASKA Pharmaceutical Co. Ltd. | |||
Deferred Revenue Arrangement [Line Items] | |||
Evaluation period | 60 days | ||
Deferred revenue | 3,100 | ||
ASKA Pharmaceutical Co. Ltd. | Upfront Payment | |||
Deferred Revenue Arrangement [Line Items] | |||
Upfront option payment | $ 2,750 | ||
ASKA Pharmaceutical Co. Ltd. | Strategic Partnerships and Other License Agreements | |||
Deferred Revenue Arrangement [Line Items] | |||
Agreement termination notice period upon breach of payment obligations by the Company | 30 days | ||
Milestone payments | $ 0 | $ 0 |
X | ||||||||||
- Definition Agreement termination notice period upon of breach of payment obligations. No definition available.
|
X | ||||||||||
- Definition Evaluation Period No definition available.
|
X | ||||||||||
- Definition Payments For Upfront Fee No definition available.
|
X | ||||||||||
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
X | ||||||||||
- Definition The amount of consideration recognized during the period for the milestone or milestones. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|